Cozad Asset Management Inc. Has $913,000 Stake in Pfizer Inc. (NYSE:PFE)

Cozad Asset Management Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,424 shares of the biopharmaceutical company's stock after selling 9,660 shares during the quarter. Cozad Asset Management Inc.'s holdings in Pfizer were worth $913,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Horizon Kinetics Asset Management LLC boosted its holdings in shares of Pfizer by 7.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 100,703 shares of the biopharmaceutical company's stock valued at $2,672,000 after buying an additional 6,888 shares during the period. Curio Wealth LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $32,000. Pitti Group Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $375,000. Cibc World Markets Corp boosted its holdings in shares of Pfizer by 17.3% in the fourth quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company's stock valued at $23,936,000 after buying an additional 133,084 shares during the period. Finally, Creative Financial Designs Inc. ADV boosted its holdings in shares of Pfizer by 4.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company's stock valued at $1,191,000 after buying an additional 2,023 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded down $0.12 during trading hours on Wednesday, hitting $26.19. The company had a trading volume of 24,966,825 shares, compared to its average volume of 35,756,685. The firm has a market cap of $148.44 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The business has a fifty day moving average of $26.21 and a 200-day moving average of $27.09. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.